Virtu Financial LLC Takes Position in Becton, Dickinson and Company $BDX

Virtu Financial LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,005 shares of the medical instruments supplier’s stock, valued at approximately $2,136,000.

Several other large investors have also added to or reduced their stakes in the business. Cambient Family Office LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $217,000. WealthPoint Financial LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $220,000. Van Diest Capital LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $364,000. Compound Planning Inc. lifted its position in shares of Becton, Dickinson and Company by 72.9% during the 4th quarter. Compound Planning Inc. now owns 2,887 shares of the medical instruments supplier’s stock valued at $560,000 after acquiring an additional 1,217 shares during the period. Finally, Invesco Ltd. boosted its stake in Becton, Dickinson and Company by 48.5% during the fourth quarter. Invesco Ltd. now owns 3,790,490 shares of the medical instruments supplier’s stock worth $735,620,000 after acquiring an additional 1,237,507 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the transaction, the executive vice president owned 14,272 shares of the company’s stock, valued at $2,161,922.56. This trade represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,013 shares of company stock worth $593,434 in the last 90 days. 0.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on BDX shares. Piper Sandler decreased their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. TD Cowen cut their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Bank of America cut their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Finally, Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $181.00.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $143.99 on Friday. The company has a fifty day simple moving average of $148.89 and a 200 day simple moving average of $172.31. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $39.67 billion, a P/E ratio of 36.45, a PEG ratio of 10.19 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the company posted $3.35 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.